New Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress

Tool to Inform Global Cancer Value Debate

PARIS, Oct. 31, 2016 /PRNewswire/ -- The 2016 World Cancer Congress (WCC) in Paris - a global gathering of more than 3,500 cancer experts - will be the setting for the introduction of a new, enhanced version of the PACE Continuous Innovation Indicators™ (CII) by PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative. The purpose of the CII - the first evidence-based, customizable online tool to review progress against cancer over time - is to inform public policy discussions and other efforts to accelerate continuous innovation against cancer. The tool is now even easier to use due to an interactive user interface and enhanced data comparison capabilities in a total of 12 cancer types. The CII may be accessed at

The new CII will be featured at WCC in a poster presentation entitled, "Assessing the Evidence Supporting New Cancer Treatments: Phase III and Beyond." A presentation of the poster will take place on Wednesday, November 2, between 10:30 a.m. and 11:00 a.m. CEST, in E-pod 2 at the Palais des Congrès. It will be conducted by Silvia Paddock, Ph.D., lead CII researcher at Rose Li and Associates, a U.S.-based research firm that developed the CII for PACE.

Advancing the value discussion in cancer care
"Cancer is a very complex disease and most progress against it has not resulted from major breakthroughs, but rather, from continuous innovation or step-by-step advances over time," said Scott Shortenhaus, Director, U.S. PACE, Policy and Advocacy at Lilly Oncology. "The PACE CII systematically gathers objective data to help us understand how progress against cancer is achieved and is therefore an essential tool to use alongside the new frameworks developed by oncology-related organizations and institutions to define the value of cancer treatments."

According to Mr. Shortenhaus, data provided by the CII will help inform when and how a new cancer treatment should be evaluated and, by increasing our understanding of the research gaps and unmet needs within each cancer, demonstrate how a new cancer therapy adds value to the current armament of available treatments.

"This historical perspective and the reality of progress in cancer care are currently missing from the value frameworks," said Mr. Shortenhaus. "Therefore, Lilly's PACE initiative felt it essential to create a user-friendly version of the CII so that as many individuals who influence the course of cancer progress - including researchers, policymakers, health policy experts and patient advocates - are able to use it on demand for a wide variety of analyses."

Advocacy community reaction to the new CII has been very positive to date. Following is a sampling of feedback:

Advancing our knowledge of cancer progress
The CII enables users to: visualize progress against cancer over time; gain a better understanding of the evolution of cancer treatment progress and value; and consider the potential impact of policy reforms that affect the speed of continuous innovation and patient access. The new version of the tool provides enhanced data comparison capabilities in a total of 12 tumor types: breast, colorectal, endometrial, gastrointestinal stromal, kidney, liver, lung, pancreatic, prostate, skin (melanoma), stomach, and testicular.

At the heart of the CII are thousands of pieces of evidence curated and coded by trained analysts from authoritative, published sources, such as clinical trial records and meta-analyses, observational studies and historical references. The tool, which provides a layered interface with a range of information, generates summary graphs from which a user can access supporting evidence and additional information. The CII is available for use at no cost through an interactive online interface at

About PACE
PACE, now in its fifth year, is a global collaboration that encourages public policies and healthcare decisions that speed the development of new medicines, assure cancer treatments respond to the needs and qualities of individual patients, and improve patient access to the most effective cancer medicines. PACE engages key oncology stakeholders, including: patients, advocacy, payers, policymakers, providers, the public, researchers and politicians. To learn more about PACE, please visit

About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

About Eli Lilly and Company (NYSE:LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and  

Refer to: Carole Copeland;; 317.610.6196 
               Dennis da Costa;; 914.645.7553

Eli Lilly and Company logo.

Logo -

To view the original version on PR Newswire, visit:

SOURCE Eli Lilly and Company

News Provided by Acquire Media

Close window | Back to top